Are you a Health Professional? Jump over to the doctors only platform. Click Here

Slyn Both (for both Men & Women) capsules

Print Friendly, PDF & Email

Slyn Both (for both Men & Women) capsules pose a serious risk to your health and should not be taken.

Related information

slyn both capsules image

The Therapeutic Goods Administration (TGA) has tested a product labelled as Slyn Both (for Men and Women) and found that:

  • it contains the undeclared substances Fluoxetine  and Orlistat.
  • consumers are advised that both Fluoxetine and Orlistat are prescription-only medicines.

The supply of Slyn Both (for Men & Women) capsules is illegal.

Slyn Both (for Men & Women) capsules have not been assessed by the TGA for quality, safety or efficacy as required under Australian legislation, and the place of manufacture is not approved by the TGA.

Information for consumers

  • Stop taking Slyn Both (for Men & Women) capsules and take any remaining capsules to your local pharmacy for safe disposal.
  • If you have any concerns arising from your use of this product, consult your health care practitioner.

Action the TGA is taking

The TGA is working with Australian Customs and Border Protection Services (ACBPS) to help stop future shipments of Slyn Both (for Men & Women) capsules from entering Australia.

If these capsules are found at the border by ACBPS they will be seized and destroyed.

The TGA is advising consumers to exercise extreme caution when purchasing medicines from unknown overseas Internet sites. Products purchased over the Internet:

  • may contain undisclosed and potentially harmful ingredients
  • may not meet the same standards of quality, safety and efficacy as those approved by the TGA for supply in Australia.

Report counterfeit medicines and medical devices

If you are worried about counterfeit medicines or medical devices, and want to report an issue, you can report the matter to the TGA:

Phone:1800 020 653
Online:Report a perceived breach of the Therapeutic Goods Act or questionable practices relating to therapeutic products

(Source: Therapeutic Goods Administration)

Print Friendly, PDF & Email


Posted On: 30 August, 2014
Modified On: 22 July, 2015


Created by: myVMC